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Summary Inhalation therapy is likely to continue to dominate asthma treatment.
The pressurised metered dose inhaler (pMDI) accounts for most of the inhaler market
world-wide, but is inefficient and difficult to use. Dry powder inhalers (DPIs) have
several advantages over MDIs. They are breath-activated, easy and convenient to use
and environmentally friendly. The Turbuhalers is the most widely used DPI, offering
good deposition with sufficient inspiratory flow, but it provides no confirmation of
dosing, exhibits high dose variation, has a high intrinsic resistance, and inspiratory
flow profile-dependent drug deposition. The Novolizers (VIATRIS, Frankfurt,
Germany) is a new DPI which has several characteristics of an ‘ideal’ inhaler. It is
convenient and easy to use, demonstrate and teach, provides accurate and
consistent drug delivery and provides patients with feedback of dose taken. The
Novolizers is a promising new delivery system for inhalation therapy.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The goals of asthma therapy are to minimise
exacerbations, to alleviate symptoms and to con-
trol inflammation.1 Successful management de-
pends on adequate delivery of medication,
particularly controller therapy, to target sites
within the lung. However, most patients cannot
use their inhalers correctly, and many are non-
compliant with their treatment regimens. There
are several reasons why patients do not comply
with therapy. In order to facilitate compliance we
should keep treatments simple, persuade patients
of treatment effectiveness, minimise dosing regi-
mens, but most important of all, ensure that
patients can use their inhalers correctly. Delivery
of drugs by inhalation has dominated asthma
therapy for more than 30 years, and will likely
continue to do so for the next 10–15 years. It is
essential that we identify all of the characteristics
of an inhaler device that could optimise delivery of
drug, not just to the large but also to the small
airways.
MDIs versus DPIs
Pressurised metered-dose inhalers (pMDIs) have
been the dominant means of delivery of drug to
the lungs for the last 30 years, and world-wide,
they still constitute more than 80% of the global
market. However, they have a number of disadvan-
tages both in terms of effectiveness and usability.
The most prescribed MDIs are inefficient and are
not user friendly. Typically, they deliver only about
1/3 of the amount of drug to the lungs compared
with the newer dry powder inhalers (DPIs). Table 1
summarises several studies which investigated lung
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Results for MDIs showed that between 8–16% of the
metered dose was deposited in the lungs. DPIs
fared slightly better. The old fashioned Spinhalers
showed lung deposition rates between 7% and 20%
compared to approximately 12% for the Diskhalers
(GlaxoSmithKline, UK), which was one of the early
DPIs. Most of the deposition studies have been done
with the Turbuhalers (AstraZeneca, UK) which
deposits between 10% and 30% of the metered dose
into the lungs. A new DPI, the Novolizers (VIATRIS,
Frankfurt, Germany) shows lung deposition of 32%.2
MDIs require good co-ordination between dose
activation and inhalation in order to ensure correct
inhalation and deposition of the drug into the
bronchial tree. Misuse of pMDIs, which is mainly due
to poor co-ordination, is frequent and associated
with poorer asthma control in inhaled corticoster-
oid-treated patients with asthma.3 Pressurised MDIs
also require an optimal inspiratory flow, a full
inspiration from functional residual capacity and a
breath hold of at least 6 s.4 Therefore, correct use
of these inhalers requires intensive training by the
physician and regular technique re-testing may also
be necessary.5 For example, some MDIs require
shaking before use in order to thoroughly mix drug
and propellant; users often forget this which makes
drug delivery unreliable. As many as 90% of patients
cannot use their MDI correctly.6 Common mistakes
include failure to continuously inhale slowly after
activation of the inhaler, failure to exhale fully
before the inhalation,7,8 activation the inhaler
before inhalation or at the end of inhalation and
concluding inhaler activation while holding
breath.8,9
Deposition rates with MDIs depend on inhalation
technique.9 MDIs can be used with a spacer device
to improve drug deposition in the lungs, but this
device is very bulky. However, use of an MDI without
a spacer device results in high deposition of the
therapeutic agent in the mouth and pharynx.10 It is
worth noting that there are significant differences
in dose output from different combinations of MDIs
and spacers.11 In addition, MDIs require priming if
they haven’t been used for a lengthy period of
time, have no inhalation control mechanism or dose
counter and contain propellants which are not
environmentally friendly (e.g. chlorofluorocarbons,
CFCs). These are being phased out due to their
depletion of atmospheric ozone layers.12 The
replacement for CFCs, hydrofluoroalkanes (HFAs),
do not destroy ozone layers, but are known to be up
to 2000 times more potent greenhouse gases than
carbon dioxide. Lubricants and CFCs in MDIs may
cause bronchoconstriction13 and can blast the back
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Table 1 Summary of studies which investigated lung deposition achieved with pressurised metered dose inhalers
and dry powder inhalers.
Device Substance Lung deposition (%) Reference
Metered dose inhalers
MDI Terbutaline 9.1 Borgstrom and Nilsson26
16.7 Newman et al.27
8.2 Borgstrom et al.28
MDI Budesonide 15.0 Thorsson et al.14
Dry powder inhalers
Device Substance PIF (l/min) Lung deposition (%) Reference
Spinhalers DSCG 10 Richards et al.29
14.2 Neale et al.30
Rotahalers DSCG 9.0 Vidgren et al.31
Salbutamol 9.1 Zainudin et al.32
Easyhalers Salbutamol 24.0 Vidgren et al.33
Diskhalers Salbutamol 11.4 Melchor et al.34
Turbuhalers Terbutaline 57 26.9 Borgstrom et al.35
58 19.0–22.0 Borgstrom et al.28
Turbuhalers Budesonide 52 32 Thorsson et al.14
36 14.8 Borgstrom et al.36
58.1
Novolizers Budesonide 45 19.9 Newman et al.2
60 25.0
90 32.1
DSCG: disodium chromoglycate; PIF: peak inspiratory flow; MDI: metered dose inhaler.
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of the throat stopping the patient from inhaling
(the ‘cold freon’ effect).
DPIs, as a class of delivery device, have numerous
advantages over pMDIs. They are breath activated,
precluding the need for the patient to co-ordinate
actuation with inhalation. This assists the effec-
tive drug delivery to the lungs. Indeed, Thorrson
and colleagues14 showed that in healthy volunteers
lung deposition of budesonide through the Turbu-
halers was over twice that through a pMDI (32%
versus 15% respectively) (Fig. 1). This result
suggests that the same degree of asthma control
can be achieved with a lower dose of budesonide
using the Turbuhalers, thus reducing the risk of
unwanted systemic effects. Agertoft and Peder-
sen15 showed that DPIs are more effective than
pMDIs for the treatment of asthma. Budesonide
delivered through the Turbuhalers produced
equivalent clinical improvement compared to
double the dose of budesonide delivered
through the Nebuhalers in children with perennial
asthma (Fig. 2), indicating that the dose of
budesonide should be reduced when patients
are switched from Nebuhalers to Turbuhalers
treatment.15
DPIs also do not contain environmentally un-
friendly propellants and do not produce a cold
sensation on inhalation. Additionally, patients
often express a preference for DPIs. For example,
in elderly patients breath-activated inhalers are
used correctly and are preferred by patients over
conventional MDIs.16
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Figure 1 Distribution of budesonide deposition delivered by the Turbuhalers or pressurised metered dose inhaler in
healthy volunteers. Reprinted with permission from: Thorsson L, Edsbacker S, Conradson TB. Lung deposition of
budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler. Eur Respir J 1994, 7:1839–1844. GI:
gastrointestinal.
Figure 2 Efficacy of budesonide delivered by Nebuhalers or Turbuhalers in children with perennial asthma (n ¼ 240).
Reprinted with permission from Agertoft L, Pedersen SE. Budesonide administered via Turbuhalers and a nebulator.
Ugeskr Laeger 1994, 156:4134–4137.
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Disadvantages of specific DPIs
There are several DPIs currently on the market or
being developed by the pharmaceutical industry.
These devices are divided into single dose devices,
multiple unit dose devices or multidose devices.
The Spinhalers and Aerolizers (Novartis) are single
dose devices. Doses are individually loaded into
gelatine capsules or blisters, each of which is
loaded into the inhaler immediately before use.
The Diskhalers and Diskuss (GlaxoSmithKline) are
examples of multiple unit dose devices as they
contain a series of capsules or blisters. With
multidose or reservoir devices the drug is metered
from a reservoir of freely flowing powder (e.g.
Novolizers, Turbuhalers). Although DPIs, as a class
of delivery devices, offer both the patient and
physician several advantages over pMDIs, individu-
ally they do have some limitations of design, cost-
effectiveness and user-friendliness.
Single unit dose devices
The Aerolizers is a modern day Spinhalers.
Limitations of this device include the fact that
there is no feedback on deposition. Additionally,
high inspiratory flow must be achieved to generate
a fine particle fraction.17 For each inhalation a new
capsule needs to be inserted into the device, which
does allow for dose counting but is not very
convenient, and the inhalation process must be
repeated until the capsule is empty. This may give
rise to high dose variability. The Aerolizers is
approved for only 50 capsules, and high tempera-
tures can soften capsules making them difficult to
perforate.
Multiple unit dose devices
The Diskhalers was the forerunner of the Diskuss,
and is still used to some degree in the UK, although
it is complicated to use. An inherent design flaw of
this early multiple unit dose device is that blisters
must be frequently changed and the device cleaned
before refilling. In addition, the device can be used
for only 3 months, so it is not very cost-effective.
The Diskuss overcame some of these problems, but
it contains only 60 doses. It is a more sophisticated
device, but unlike the Diskhalers it is not refill-
able. In some cases the metered dose is not
completely emptied as the patient is not able to
inspire fully. The mouthpiece is also not user-
friendly, and it is costly to produce because of the
level of complexity.
Multidose devices
The Turbuhalers is the most frequently prescribed
DPI as it offers good deposition with sufficient
inspiratory flow. However, it does have some
disadvantages. For example, there is no feedback
to the patient that medication has been success-
fully delivered. The patient does not taste, smell or
even feel the delivered particles of the dose that is
inhaled. There is no inhalation control mechanism,
the dose counter is limited, there is high dose to
dose and device to device variation,18 and the
device is not refillable. The Turbuhalers also has a
high intrinsic resistance, requiring a relatively high
inspiratory flow of 60 l/min for optimal drug
delivery. This may not be achievable, especially in
younger children, elderly patients and other pa-
tients with a low peak inspiratory flow rate. Finally,
the particle size inhaled is very much dependent on
the patients’ inspiratory flow rate,19 and the
amount of drug released from the device is reduced
under conditions of high humidity.20
The Novolizers: an ideal inhaler?
Users’ dissatisfaction with pMDIs has led to the
concept of an ‘ideal’ inhaler.21,22 Discussions with
asthma patients (or their parents, in the case of
children) and healthcare professionals have led to
the following characteristics being drawn up for the
‘ideal’ inhaler: accurate and consistent in effective
drug delivery; easy and convenient to use; easy to
teach, learn and remember how to use correctly;
capable of delivering a range of drugs; accurate
dose counter; patient feedback of dose taken;
convenient to carry; robust; visually appealing
to the patient; easily identifiable in terms of
the drug/strength contained in the inhaler; and
propellant-free.
The Novolizers, the multidose DPI from VIATRIS,
is a breath-activated, refillable, multi-use inhala-
tion device. Both 100 and 200 dose cartridges are
available, and these are offered in sealed contain-
ers. It has an innovative design which combines
simplicity of use with effective performance;
which results in assured drug delivery. As the
Novolizers does not contain propellant it is an
ecological and attractive alternative for the admin-
istration of a variety of drugs for inhalation. The
Novolizers closely meets the characteristics sought
in an ‘ideal’ inhaler. In contrast, the Turbuhalers,
has several characteristics which provide uncer-
tainty both for the patient and the healthcare
professional.
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The Novolizers has several innovative features
offering unique inhalation control and feedback
which give it an advantage compared to other
inhalers (Fig. 3). The Novolizers has a multiple
inhalation control system so that for the first
time patients and doctors know that the pre-
scribed drug has reached the lungs. The patient
receives information as to whether the necessary
flow has been achieved, and whether or not the
powder has been releasedFvisually and acousti-
cally as well as by taste. Thus, the Novolizers is
easy to use and to teach, as it guides patients
through the inhalation procedure. In contrast,
the Turbuhalers provides only limited feedback to
the patient, and has a limited dose counter.
A novel feature of the Novolizers is a flow
trigger valve system that releases the powder
only after a certain flow rate has been achieved
(35 l/min).23 This mechanism ensures sufficient
drug delivery at the site(s) where it is needed.
The Turbuhalers does not confirm drug de-
position as observed for the Novolizers. The
particle size emitted from the Turbuhalers also
depends upon the flow profile generated by the
patient.19 In addition, the Novolizers gives sig-
nificantly greater lung deposition and less orophar-
yngeal deposition than the Turbuhalers when both
devices are used optimally with maximal inspira-
tory effort.2
The quality of the aerosol emitted from the
Novolizers is assured by a helix or cyclone in the
mouthpiece.24 The Novolizers delivers a precise
and consistent dose over the cartridge lifetime
independent of temperature and humidity, with
minimal dosage variability between actuations.24 It
is functionally reliable and hygienic in ‘real-life’
situations.25 This is not the case for the Turbuha-
lers. If, for example, the Turbuhalers is stored at
70% humidity, the amount of drug released from the
device is reduced within 2 h and this reduction in
dose lasts for up to 4 days.20 Even in the absence of
high humidity conditions, there is a high dose to
dose and device to device variation with the
Turbuhalers.18
Compared to other DPIs, the Novolizers is
characterised by low to medium airflow resistance
and a smooth increase of pressure drop at higher
flow rates during inhalation. This makes it easier
for the patient to use the device for effective drug
dispersion and deposition, and may thus improve
compliance. Assuming a mean flow rate of 60 l/min
during inhalation, patients have to overcome a
resistance 2.5 times higher with the Turbuhalers
compared with the Novolizers. Flow rates o60 l/
min through the Turbuhalers result in high oral and
low lung drug deposition. The Novolizers may be
considered cost effective as it is robust (can be
used every day for up to 1 year), is refillable, and
ARTICLE IN PRESS
Figure 3 Innovative design features of the Novolizers which make it an ‘ideal’ inhaler.
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ensures deposition of therapeutic agent into the
bronchial tree.
Conclusion
Asthma therapy is optimally given by inhalation.
The inhaler device used to deliver this medication
is one of the most important factors in asthma
management decisions. The Novolizers is an
innovative DPI with several of the characteristics
sought in an ‘ideal’ inhaler, and overcomes many of
the problems observed with other DPIs. It is safe,
reliable, easy to use and carry, and ensures
deposition of the drug into the lungs. The multiple
control feedback mechanism gives unique confi-
dence and reassurance that medication has been
successfully delivered. These features, as well as
patient satisfaction with the device are likely to
improve compliance. The cyclone design ensures
high quality aerosol release. The low resistance of
the device, as well as the relative independence of
particle size from flow rate, means that the
Novolizers is also suitable for patients with more
severe airflow obstruction. The Novolizers is a
cost-effective device as it is refillable and is
virtually impossible to use incorrectly. It is a real
step forward in the development of DPIs and is a
promising new delivery system for inhalation
therapy.
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